CLYMClimb Bio, Inc.

$522M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$15M

Net Income

-$13M

EPS (Diluted)

$-0.19

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$12M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$182M

Total Liabilities

$5M

Stockholders' Equity

$177M

Cash & Equivalents

$26M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$15M	-$12M	-26.9%
Net Income	-$13M	-$9M	-44.9%

CLYM Q3 2025 Earnings — Climb Bio, Inc. Revenue & Financial Results | Market Cap Arena